Population
Recombinant human alpha-tropomyosin expressed in Escherichia coli
Comparison
Asp175Asn and Glu180Gly missense mutations in… vs Wild-type alpha-tropomyosin
Design
Preclinical
Authors
Loading...
These biophysical changes may impair thin filament regulation in HCM; hypothesis-generating for in vivo validation and mechanism-targeted therapies.
Familial hypertrophic cardiomyopathy-causing mutations in alpha-tropomyosin alter the protein's local stability and conformational response to myosin S1 binding, potentially disrupting thin filament regulation.
Golitsina et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: